Use of Extracellular Monomeric Ubiquitin as a Therapeutic Option for Major Depressive Disorder
Authors:
- José Luis Maldonado-GarcíaJosé Luis Maldonado-García
- Lissette Haydee García-MenaLGLissette Haydee García-Mena
- Danelia Mendieta-CabreraDMDanelia Mendieta-Cabrera
- Gilberto Pérez-SánchezGilberto Pérez-Sánchez
- Enrique Becerril-VillanuevaEnrique Becerril-Villanueva
- Samantha Alvarez-HerreraSamantha Alvarez-Herrera
- Toni HombergTHToni Homberg
- Luis Vallejo-CastilloLuis Vallejo-Castillo
- Sonia Mayra Pérez-TapiaSPSonia Mayra Pérez-Tapia
- Martha C. Moreno-LafontMMMartha C. Moreno-Lafont
- Daniel Ortuño-SahagúnDaniel Ortuño-Sahagún
- Lenin PavónLenin Pavón
Open Access
- 27 June 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (7) , 841
Abstract
Major depressive disorder (MDD) is a mood disorder that has become a global health emergency according to the World Health Organization (WHO). It affects 280 million people worldwide and is a leading cause of disability and financial loss. Patients with MDD present immunoendocrine alterations like cortisol resistance and inflammation, which are associated with alterations in neurotransmitter metabolism. There are currently numerous therapeutic options for patients with MDD; however, some studies suggest a high rate of therapeutic failure. There are multiple hypotheses explaining the pathophysiological mechanisms of MDD, in which several systems are involved, including the neuroendocrine and immune systems. In recent years, inflammation has become an important target for the development of new therapeutic options. Extracellular monomeric ubiquitin (emUb) is a molecule that has been shown to have immunomodulatory properties through several mechanisms including cholinergic modulation and the generation of regulatory T cells. In this perspective article, we highlight the influence of the inflammatory response in MDD. In addition, we review and discuss the evidence for the use of emUb contained in Transferon as a concomitant treatment with selective serotonin reuptake inhibitors (SSRIs).Keywords
Funding Information
- Conahcyt (CF-2023-G-836, SIP-IPN 20241740, 822954, 594780)
This publication has 152 references indexed in Scilit:
- Complement C3 and C3aR mediate different aspects of emotional behaviours; relevance to risk for psychiatric disorderBrain, Behavior, and Immunity, 2022
- The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)PharmacoEconomics, 2021
- Transfer Factor: Myths and FactsArchives of Medical Research, 2020
- Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controlsBrain, Behavior, and Immunity, 2020
- Gut Microbiota and the Neuroendocrine SystemNeurotherapeutics, 2018
- Regulation of the Hypothalamic‐Pituitary‐Adrenocortical Stress Response2016
- Mechanisms of cytokine-induced behavioral changes: Psychoneuroimmunology at the translational interfaceBrain, Behavior, and Immunity, 2009
- Depressive disorders and immunity: 20 years of progress and discoveryBrain, Behavior, and Immunity, 2007
- Ubiquitin: structures, functions, mechanismsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2004
- The Cholinergic Anti-inflammatory Pathway: A Missing Link in NeuroimmunomodulationMolecular Medicine, 2003